Resource Logo
Business Wire

Ardea Biosciences Reports Recent Accomplishments and First




 

Restructuring to Focus Company on Clinical - Stage Programs

SAN DIEGO - Ardea Biosciences, Inc. (Nasdaq: RDEA), a biotechnology company focused on the development of small - molecule therapeutics for the treatment of gout, human immunodeficiency virus (HIV), cancer and inflammatory diseases, today reported recent accomplishments and financial results for the first quarter ended March 31, 2009 and announced a restructuring of operations. The restructuring is intended to conserve financial resources by focusing the Company on its clinical - stage programs.



 


Copyright © 2009 -Business Wire, Publisher. All rights reserved to Business Wire.Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. Business Wire.

Information in this article was accurate in May 8, 2009. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.